Gilead Sciences (GILD) Donates Remdesivir to Uganda

On June 12, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced a donation of much than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to enactment effect efforts for the existent outbreak of Ebola Bundibugyo microorganism disease. Anu Osinusi, Vice President of Clinical Development, Virology astatine Gilead Sciences, said the institution recognizes the urgency of planetary wellness emergencies and is moving with partners to enactment the outbreak response.

On June 8, 2026, Merck (MRK) and Gilead Sciences, Inc. (NASDAQ:GILD) announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 survey evaluating Trodelvy successful operation with KEYTRUDA, compared with KEYTRUDA monotherapy, successful definite patients with antecedently untreated metastatic non-small compartment lung crab whose tumors expressed PD-L1. The determination followed a proposal from the outer Data Monitoring Committee aft its reappraisal of the pre-specified last investigation of progression-free endurance and interim investigation of wide survival. The companies said a numerical betterment successful progression-free endurance was observed, but did not scope statistical significance, portion the probability of achieving statistically important wide endurance astatine the planned last investigation was unlikely.

On June 2, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced Phase 3 results successful superior biliary cholangitis showing that Livdelzi led to importantly much patients achieving normalization of alkaline phosphatase, oregon ALP, compared with placebo aft 52 weeks. The superior endpoint was defined arsenic ALP little than oregon adjacent to 1.0 precocious bounds of mean and a greater than oregon adjacent to 15% alteration from baseline. Cynthia Levy of the University of Miami Miller School of Medicine said the IDEAL results further enactment the efficacy and information illustration of Livdelzi and widen its grounds basal to a broader colonisation of radical surviving with PBC.

Gilead Sciences, Inc. (NASDAQ:GILD) discovers, develops, and commercializes medicines successful areas of unmet aesculapian request successful the United States, Europe, and internationally.

While we admit the imaginable of GILD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.